SBRI-backed Owlstone Medical have announced that GSK will incorporate their Breath Biopsy platform into the clinical development programme of one of the novel drug candidates in its respiratory disease pipeline.
GSK will use Owlstone Medical’s Breath Biopsy platform as part of a Phase II clinical trial to assess whether the right patient for the right treatment can be identified, as well as assessing the treatment effects of a novel drug for chronic obstructive pulmonary disease (COPD).
The platform will be used to capture Volatile Organic Compounds (VOCs) in breath completely non-invasively, and analyse them with high sensitivity. The breath samples will be collected from patients participating in the clinical trial using Owlstone Medical’s CE-marked ReCIVA Breath Sampler, before shipping to the company’s clinical lab for analysis.
Karen Livingstone, National Director of SBRI Healthcare, commented: “This is exciting news for SBRI backed Owlstone Medical. It represents a significant step forward in validating the use of their Breath Biopsy® platform to analyse breath biomarkers.
“We are delighted to see Owlstone go from strength to strength following their SBRI Healthcare contract.”
The announcement comes on the same day as David Connell’s independent review of how the UK government can maximise the impact of the SBRI, which found the programme to be “the best role model”, with a recommendation that the programme be developed and built upon.